Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.

We review the efficacy, tolerability and safety of low-dose thalidomide in the treatment of refractory disfiguring rash in 16 patients with cutaneous manifestations of lupus. Rashes, which included discoid lupus erythematosus (DLE), subacute cutaneous lupus (SCLE), photosensitive malar rash and non-specific chronic erythema, were diagnosed on clinical grounds, supported by skin biopsy in 11/16 patients. Using starting doses of 50-100 mg/day, 7/16 (44%) patients gained complete or near-complete remission of skin disease and 6/16 (37%) partial remission. Three out of 16 patients failed to respond. Maximum benefit was achieved within 16 weeks in all patients. Doses of 25-50 mg/day were effective in maintaining response. Rapid relapse occurred in 6/8 (75%) patients following drug withdrawal, but the response to thalidomide in those requiring repeat courses appeared to be maintained. There was no detectable improvement in systemic disease. One patient developed symptoms of mild peripheral neuropathy which resolved on drug withdrawal. Our experience suggests that thalidomide is effective in the treatment of severe skin manifestations of lupus refractory to other treatment and can be used safely in specialist rheumatological practice.

[1]  C M Lockwood,et al.  The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures , 1995, Clinical and experimental immunology.

[2]  R. Powell,et al.  Thalidomide--the way forward. , 1994, Postgraduate medical journal.

[3]  R. Powell,et al.  Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. , 1994, Annals of the rheumatic diseases.

[4]  R. Powell,et al.  Guideline for the clinical use and dispensing of thalidomide. , 1994, Postgraduate medical journal.

[5]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  E. Atra,et al.  Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. , 1993, Clinical and experimental rheumatology.

[7]  G. Kaplan,et al.  The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. , 1993, The Journal of infectious diseases.

[8]  J. Guilhou,et al.  Thalidomide for systemic lupus erythematosus , 1992, The Lancet.

[9]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[10]  E. Shannon,et al.  Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. , 1985, Leprosy review.

[11]  R. Barnhill,et al.  Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. , 1984, Journal of the American Academy of Dermatology.

[12]  E. Grosshans,et al.  Thalidomide Therapy for Inflammatory Dermatoses , 1984, International journal of dermatology.

[13]  M. Hasper.  Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients. , 1983, Archives of dermatology.

[14]  R. Happle,et al.  Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus , 1983, The British journal of dermatology.

[15]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[16]  B. Naafs,et al.  Thalidomide treatment of subacute cutaneous lupus erythematosus , 1982, The British journal of dermatology.

[17]  D. O'Sullivan,et al.  Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. , 1968, Journal of neurology, neurosurgery, and psychiatry.

[18]  M. Joseph.  THALIDOMIDE AND CONGENITAL ABNORMALITIES , 1962, Developmental medicine and child neurology.

[19]  M. Kremer,et al.  Neuropathy After Intake of Thalidomide (Distaval) , 1961, British medical journal.

[20]  J. T. de las Aguas.  Thalidomide in the treatment of lepra reactions. , 1971, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.